Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

US10457648B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10457648-B2
Application numberUS-201515514188-A
CountryUS
Kind codeB2
Filing dateSep 25, 2015
Priority dateSep 26, 2014
Publication dateOct 29, 2019
Grant dateOct 29, 2019

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)-propan-1-one). The present disclosure additionally relates to various compounds that are intermediates employed in these processes.

First claim

Opening claim text (preview).

What is claimed is: 1. A process for preparing a compound of Formula I: or a salt thereof, the process comprising: (a) cyclizing a compound of VI b : or a salt thereof to form a compound of Formula (V); wherein each X is hydroxyl; (b) brominating the compound of Formula V or a salt thereof with a brominating agent to form a compound of Formula IV: or a salt thereof, wherein Y is bromo; (c) contacting the compound of Formula IV with a piperazine compound having the structure: or a salt thereof, wherein Lv is a leaving group and R 1 is an amino protecting group to form a compound of Formula III: or a salt thereof; and (d) contacting the compound of Formula III with a metalating agent to form the compound of Formula I, or a salt thereof; wherein R 1 is hydrogen or an amino protecting group. 2. The process of claim 1 , wherein Lv is selected from hydrogen and a halogen, and R 1 is selected from acetyl, trifluoroacetyl, phthalimidyl, benzyl, triphenylmethyl, benzylidenyl, p-toluenesulfonyl, p-methoxybenzyl, tertbutyloxycarbonyl, 9-fluorenylmethyloxycarbonyl and carbobenzyloxy. 3. The process of claim 1 , wherein the brominating agent is selected from bromine, bromotrimethylsilane, phosphorus oxybromide, N-bromosuccinimide, and phosphorus tribromide. 4. The process of claim 1 , wherein distillation is used to remove volatile byproducts during the bromination reaction. 5. The process of claim 1 , wherein the process comprises contacting the compound or a salt thereof of Formula VI b with a formamidine salt to cyclize the compound of Formula VI b , or a salt thereof. 6. The process of claim 1 , wherein R 1 is selected from acetyl, trifluoroacetyl, phthalimidyl, benzyl, triphenylmethyl, benzylidenyl, p-toluenesulfonyl, p-methoxybenzyl, tertbutyloxycarbonyl, 9-fluorenylmethyl oxycarbonyl and carbobenzyloxy. 7. The process of claim 1 , wherein the metalating agent is an organometal compound. 8. The process of claim 7 , wherein the organometal compound is selected from isopropylmagnesium chloride, isopropylmagnesium chloride lithium chloride complex, sec-butylmagnesium chloride, n-butyllithium, sec-butyllithium, t-butyllithium, lithium tri-n-butylmagnesiate, lithium triisopropylmagnesiate, and lithium (isopropyl)(di-n-butyl)magnesiate. 9. The process of claim 1 , wherein R 1 is tertbutyloxycarbonyl. 10. The process of claim 1 , wherein Lv is hydrogen. 11. The process of claim 1 , wherein the metalating agent is an organomagnesium compound. 12. The process of claim 11 , wherein the organomagnesium compound is a C 1 -C 6 alkylmagnesium halide. 13. The process of claim 11 , wherein the organomagnesium compound is isopropylmagnesium chloride or sec-butylmagnesium chloride. 14. The process of claim 11 , wherein the organomagnesium compound is isopropylmagnesium chloride.

Assignees

Inventors

Classifications

  • Two or more oxygen, sulphur or nitrogen atoms · CPC title

  • by reactions not involving the formation of cyano groups · CPC title

  • acting on carbon to nitrogen bonds other than peptide bonds (3.5) · CPC title

  • C07D239/70Primary

    condensed with carbocyclic rings or ring systems · CPC title

  • Two oxygen atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10457648B2 cover?
The present disclosure relates to processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds, and more particularly relates to processes for preparing (R)-4-(5-methyl-7-oxo-6,7-dihydro-5H-cyclopenta[d] pyrimidin-4-yl)piperazine and N-protected derivatives thereof, which may be used as an intermediate in the synthesis of Ipatasertib (i.e., (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-h…
Who is the assignee on this patent?
Hoffmann La Roche, Genentech Inc
What technology area does this patent fall under?
Primary CPC classification C07D239/70. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).